Key result
Avibirnavirus VP3 inhibits antiviral innate immunity by blocking TBK1-TRAF3 complex formation and IRF3 activation, while K33-linked polyubiquitination of TRAF3 enhances TBK1 interaction.
Why the study?
Type I interferon is critical against virus infection including Avibirnavirus, but many viruses have developed strategies to antagonize host innate antiviral immunity during coevolution.
The study identifies mechanisms by which Avibirnavirus VP3 antagonizes the host antiviral immune response.
No immediate clinical implications; leaves open targeted antiviral strategies against innate immune evasion pending human validation.
Type I interferon plays a critical role in the host response against virus infection, including Avibirnavirus. However, many viruses have developed multiple strategies to antagonize the innate host antiviral immune response during coevolution with the host. In this study, we first identified that K33-linked polyubiquitination of lysine-155 of TRAF3 enhances the interaction with TBK1, which positively regulates the host IFN immune response.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2021) studied Avibirnavirus infection. Avibirnavirus VP3 was evaluated on TBK1-TRAF3 complex formation and host IFN immune response. Avibirnavirus VP3 inhibits antiviral innate immunity by blocking TBK1-TRAF3 complex formation and IRF3 activation, while K33-linked polyubiquitination of TRAF3 enhances TBK1 interaction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: